Nick Braamburg

Associate

阿姆斯特丹 + 31.20.305.4237

聯絡

*Share

Nick Braamburg is a corporate lawyer whose practice centers on private equity and cross-border M&A. He advises private equity firms, financial investors, and corporates on the full transaction life cycle — from acquisitions and divestitures to management and leveraged buyouts, joint ventures, venture capital investments, and real estate transactions.

Nick brings particular depth to technology M&A and transactions in the manufacturing, chemicals, life sciences, and consumer goods industries. He also has significant experience advising on direct and indirect real estate transactions.

Recent transactions include advising: Fortino Capital on the auction sale of asset integrity management platform Cenosco to Summit Partners; Gimv in the acquisition of a majority stake in Alpine from Vendis Capital; The Scotts Miracle-Gro Company in the sale of Gavita International B.V. via a management buyout; and A-Insights in its strategic merger with Valona Intelligence.

Prior to joining Jones Day in 2024, Nick practiced at another top-tier international law firm.

執業經驗

  • MPE Partners portfolio company acquires NANUK Gear ProtectionJones Day advised MPE Partners in the acquisition and financing by portfolio company SKB Cases, LLC of NANUK Gear Protection Inc., a Québec-based provider of premium injection molded protective cases, delivering high-performance solutions for mission-critical equipment across a wide range of applications.
  • EagleTree acquires The Opus GroupJones Day advised EagleTree Capital in the acquisition and financing of The Opus Group, a purpose-built network of agency brands delivering experiential, event and brand marketing for more than 70 global companies.
  • One Equity Partners acquires BARTECJones Day advised One Equity Partners in the acquisition of BARTEC from a consortium led by Bridgepoint Credit and Alcentra.
  • BioMarin acquires Amicus Therapeutics for $4.8 billionJones Day is advising BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) in its $4.8 billion acquisition of Amicus Therapeutics (Nasdaq: FOLD).
  • EDF Invest acquires 50% of Euro Living and enters into joint venture with Savills Investment ManagementJones Day advised EDF Invest, the investment arm of global electricity leader Électricité de France (EDF SA), a global leader in low-carbon electricity generation and supply, on its acquisition of a 50% interest in Euro Living, the holding company of Savills Investment Management’s European Living Fund (EULIV).
  • Scotts Miracle-Gro sells Gavita in management buyoutJones Day advised The Scotts Miracle-Gro Company in the sale of Gavita International B.V., a leading name in professional horticultural lighting, via a management buyout.
  • A-INSIGHTS merges with Valona IntelligenceJones Day advised A-INSIGHTS in its strategic merger with Valona Intelligence to redefine competitive and market intelligence and create an unparalleled intelligence solution for globally operating enterprises.
  • Gimv invests in AlpineJones Day advised Gimv in the acquisition and financing of a majority stake in Alpine, one of the leading international consumer brands providing passive hearing protection solutions, from Vendis Capital, the founders and management team.
  • Demcon sells Dutch United Instruments stake to QED Technologies InternationalJones Day advised Demcon in the sale of its shares in Dutch United Instruments B.V., a developer of instruments for ultra-precise, contactless metrology of optical components, to QED Technologies International, a provider of advanced production and metrology solutions for precision optics and a portfolio company of QUAD-C.
  • Fortino participates in growth investment in CenoscoJones Day advised existing investor Fortino Capital Partners on its participation in the growth investment in Cenosco B.V., a leading provider of asset integrity management software, led by Summit Partners.
    •

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.